Pred-462

is gaining traction as a "best of both worlds" solution, offering digital clarity with the ruggedness required for demanding environments. Key Features at a Glance Dual Mode Capability Hytera PD462

| Question | Current Knowledge | What Remains to Be Determined | |----------|-------------------|------------------------------| | | Patent and abstract hint at PI3Kδ/ER binding. | Confirmation via crystallography or proteomics. | | Biomarker Strategy | Preliminary work on phospho‑AKT levels. | Validation of predictive biomarkers (e.g., PIK3CA mutations). | | Resistance Mechanisms | In‑vitro selection of resistant clones shows upregulation of ABC transporters. | Clinical relevance of resistance pathways. | | Formulation | Cyclodextrin‑based oral suspension used in animal studies. | Final dosage form (tablet vs. solution) and bioavailability in humans. | | Regulatory Path | IND cleared in the U.S.; IND‑like submissions planned for EU/JP. | Timeline for NDA/MAA submission contingent on Phase II data. | PRED-462

| Year | Milestone | |------|-----------| | | Hit identification via high‑throughput screening of ~2 M compounds. | | 2023 | Lead optimization; PRED‑462 selected for superior potency and ADME profile. | | 2024 | IND‑enabling toxicology completed; filing of a provisional patent. | | 2025 | First‑in‑human (FIH) Phase I trial initiated in healthy volunteers (single‑ascending dose). | | 2026 (Projected) | Expansion into Phase Ib/IIa oncology trial in estrogen‑receptor‑positive (ER⁺) breast cancer patients. | is gaining traction as a "best of both

Digital technology ensures that your voice remains crisp and clear even at the edge of the radio's range. Additionally, features like CTCSS/CDCSS | | Biomarker Strategy | Preliminary work on